EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Fremanezumab in Children and Adolescents with Episodic Migraine

Andrew D Hershey, Christina L Szperka, Piero Barbanti, Patricia Pozo-Rosich, Petra Bittigau, Steve Barash, Juline Bryson, Yoel Kessler, Yael Carmeli Schwartz, Verena Ramirez Campos, Xiaoping Ning

New England Journal of Medicine · 15.01.2026 · 394 (3) · 243-252

DOI: 10.1056/nejmoa2504546 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 15.01.2026. Verfasst von Andrew D Hershey und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Teva Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsMigraine DisordersAdolescentChildFemaleHumansMaleDouble-Blind MethodInjections, SubcutaneousSeverity of Illness IndexInjection Site ReactionErythemaTreatment Outcome

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor Antagonistsfremanezumab

Autor:innen und Institutionen

  • Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati.
  • Children's Hospital of Philadelphia, Philadelphia.
  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
  • Headache and Pain Unit, IRCCS San Raffaele, Rome.
  • San Raffaele University, Rome.
  • Headache Unit and Research Group, Vall d'Hebron Hospital and Research Institute, Universitat Autonoma de Barcelona, Barcelona.

Förderung

  • Teva Pharmaceuticals

Zitieren

APA

Hershey, A. D., Szperka, C. L., Barbanti, P., Pozo-Rosich, P., Bittigau, P., Barash, S., Bryson, J., Kessler, Y., Carmeli Schwartz, Y., Ramirez Campos, V., & Ning, X. (2026). Fremanezumab in Children and Adolescents with Episodic Migraine. New England Journal of Medicine, 394(3), 243-252. https://doi.org/10.1056/nejmoa2504546

Vancouver

Hershey AD, Szperka CL, Barbanti P, Pozo-Rosich P, Bittigau P, Barash S, et al. Fremanezumab in Children and Adolescents with Episodic Migraine. New England Journal of Medicine. 2026;394(3):243-252. doi:10.1056/nejmoa2504546

BibTeX
@article{Hershey2026,
  author = {Hershey, Andrew D and Szperka, Christina L and Barbanti, Piero and Pozo-Rosich, Patricia and Bittigau, Petra and Barash, Steve and Bryson, Juline and Kessler, Yoel and Carmeli Schwartz, Yael and Ramirez Campos, Verena and Ning, Xiaoping},
  title = {Fremanezumab in Children and Adolescents with Episodic Migraine},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {3},
  pages = {243--252},
  doi = {10.1056/nejmoa2504546}
}
Kostenlos starten →